Update shared on 03 Dec 2025
Analysts have maintained their price target for Max Healthcare Institute at ₹1,269, citing unchanged assumptions for the discount rate, revenue growth, profit margins, and future valuation multiples.
What's in the News
- Max Healthcare Institute Limited has scheduled a board meeting on November 14, 2025, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).
- Max Healthcare Institute Limited has been added as a constituent to the Nifty 50 index, reflecting its growing significance in the Indian equity market (index announcement).
Valuation Changes
- Fair Value Estimate maintained at ₹1,269 per share, showing no change in the analyst target price.
- Discount Rate unchanged at 12.76 percent, indicating a stable risk and return assumption for the stock.
- Revenue Growth effectively steady at about 29.78 percent, with only negligible rounding refinements in the model.
- Net Profit Margin essentially unchanged at about 18.46 percent, reflecting stable profitability expectations.
- Future P/E Multiple maintained at about 56.88x, with only minor decimal level adjustments and no directional shift.
Have other thoughts on Max Healthcare Institute?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.